BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31936239)

  • 1. Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer.
    Jin W
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31936239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling.
    Fan Y; Zhang B; Du X; Wang B; Yan Q; Guo L; Yao W
    Curr Cancer Drug Targets; 2024; 24(3):271-287. PubMed ID: 37670705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.
    Tanaka H; Sase H; Tsukaguchi T; Hasegawa M; Tanimura H; Yoshida M; Sakata K; Fujii T; Tachibana Y; Takanashi K; Higashida A; Hasegawa K; Ono Y; Oikawa N; Mio T
    Mol Cancer Ther; 2018 Dec; 17(12):2519-2529. PubMed ID: 30242093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer.
    Kim MS; Jeong J; Seo J; Kim HS; Kim SJ; Jin W
    Sci Rep; 2016 Sep; 6():33899. PubMed ID: 27654855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
    Drilon A; Nagasubramanian R; Blake JF; Ku N; Tuch BB; Ebata K; Smith S; Lauriault V; Kolakowski GR; Brandhuber BJ; Larsen PD; Bouhana KS; Winski SL; Hamor R; Wu WI; Parker A; Morales TH; Sullivan FX; DeWolf WE; Wollenberg LA; Gordon PR; Douglas-Lindsay DN; Scaltriti M; Benayed R; Raj S; Hanusch B; Schram AM; Jonsson P; Berger MF; Hechtman JF; Taylor BS; Andrews S; Rothenberg SM; Hyman DM
    Cancer Discov; 2017 Sep; 7(9):963-972. PubMed ID: 28578312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting TRK Proteins in Clinical Cancer Therapy.
    Lange AM; Lo HW
    Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29617282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting TRK family proteins in cancer.
    Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
    Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
    Cocco E; Lee JE; Kannan S; Schram AM; Won HH; Shifman S; Kulick A; Baldino L; Toska E; Arruabarrena-Aristorena A; Kittane S; Wu F; Cai Y; Arena S; Mussolin B; Kannan R; Vasan N; Gorelick AN; Berger MF; Novoplansky O; Jagadeeshan S; Liao Y; Rix U; Misale S; Taylor BS; Bardelli A; Hechtman JF; Hyman DM; Elkabets M; de Stanchina E; Verma CS; Ventura A; Drilon A; Scaltriti M
    Cancer Discov; 2021 Jan; 11(1):126-141. PubMed ID: 33004339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.
    Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
    Expert Opin Ther Pat; 2017 Jul; 27(7):831-849. PubMed ID: 28270021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
    Drilon A; Ou SI; Cho BC; Kim DW; Lee J; Lin JJ; Zhu VW; Ahn MJ; Camidge DR; Nguyen J; Zhai D; Deng W; Huang Z; Rogers E; Liu J; Whitten J; Lim JK; Stopatschinskaja S; Hyman DM; Doebele RC; Cui JJ; Shaw AT
    Cancer Discov; 2018 Oct; 8(10):1227-1236. PubMed ID: 30093503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in tyrosine kinase receptor (Trk) expression induced by insulin-like growth factor-1 in cultured dorsal root ganglion neurons.
    Li H; Zhang P; Fu G; Li J; Liu H; Li Z
    Brain Res Bull; 2013 Jan; 90():25-34. PubMed ID: 23022575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
    Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
    Expert Opin Ther Pat; 2017 Jun; 27(6):733-751. PubMed ID: 28270010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N; McDermott R
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
    [No Abstract]   [Full Text] [Related]  

  • 14. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation.
    Tognon C; Garnett M; Kenward E; Kay R; Morrison K; Sorensen PH
    Cancer Res; 2001 Dec; 61(24):8909-16. PubMed ID: 11751416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TrkC promotes colorectal cancer growth and metastasis.
    Kim MS; Suh KW; Hong S; Jin W
    Oncotarget; 2017 Jun; 8(25):41319-41333. PubMed ID: 28455963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TrkC plays an essential role in breast tumor growth and metastasis.
    Jin W; Kim GM; Kim MS; Lim MH; Yun C; Jeong J; Nam JS; Kim SJ
    Carcinogenesis; 2010 Nov; 31(11):1939-47. PubMed ID: 20802235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotrophin Trk Receptors: New Targets for Cancer Therapy.
    Meldolesi J
    Rev Physiol Biochem Pharmacol; 2018; 174():67-79. PubMed ID: 28884193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression of TrkC (NTRK3) in human soft tissue tumours.
    Hisaoka M; Sheng WQ; Tanaka A; Hashimoto H
    J Pathol; 2002 Aug; 197(5):661-7. PubMed ID: 12210087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
    Wang Z; Wang J; Wang Y; Xiang S; Song X; Tu Z; Zhou Y; Zhang ZM; Zhang Z; Ding K; Lu X
    J Med Chem; 2022 Apr; 65(8):6325-6337. PubMed ID: 35426680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.